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 3 
Introduction 39 
Pregnancy is a unique condition which greatly alters a women’s physiology. In order to successfully meet 40 
the demands of a growing fetus, profound hemodynamic changes occur. Early in pregnancy peripheral 41 
vascular resistance (PVR) drops, inducing a substantial increase in cardiac output (CO).1-7 CO is the amount 42 
of blood the heart pumps into the arterial system (liters/minute). It is the product of stroke volume (SV) and 43 
heart rate (HR). SV is determined by the driving force filling the ventricles (preload), the contraction 44 
strength of the ventricle and resistance against which the heart has to pump (afterload). Blood pressure (BP) 45 
is a product of CO and PVR (BP = CO x PVR), linking these 3 hemodynamic parameters into one equation. 46 
 47 
During the course of pregnancy (placental and fetal growth, delivery) and possible pregnancy complications 48 
(preeclampsia, intra-uterine growth restriction, hypertension, sepsis, postpartum hemorrhage, thrombosis), 49 
large fluctuations in these hemodynamic parameters occur.1, 8-21 Consequently, the interest in measuring 50 
these parameters during pregnancy has been growing.  51 
CO can be measured with several very different techniques. Most of them were primarily developed for use 52 
in critical care settings and non-pregnant populations. Many of them have been imported into obstetrics, 53 
however often without proper validation in pregnant women. Each technique has distinctive implications, 54 
benefits and limitations. It is of great importance to know these characteristics in order to select the most 55 
appropriate technique for the specific occasion.  56 
For example, if one wants to study hemodynamic adaptation to pregnancy in order to predict or manage 57 
hypertensive problems, intermittent but accurate measurements are appropriate. If one wants to compare 58 
findings between individuals, indexing for body composition can be important. On the other hand if one 59 
would like to monitor the hemodynamic condition during acute events, continuous operator independent 60 
trend monitoring can be more useful. 61 
Important considerations are the degree of invasiveness, the degree of operator dependency, the availability, 62 
costs, whether intermittent measurements or continuous measurements are possible, the accuracy and 63 
precision in reflecting absolute values or trends and validation in pregnancy. 64 
The use of different techniques has sometimes resulted in conflicting findings, thus limiting the possibilities 65 
of comparing studies. 66 
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This position statement aims at describing the characteristics of the different methods and standardizing the 67 
detection of CO and PVR in clinical practice and research studies on maternal hemodynamics. 68 
 69 
Physiology in pregnancy 70 
Cardiac output 71 
As stated above, already in the first trimester of pregnancy a rapid increase in CO occurs which 72 
continues throughout the second trimester.1, 22, 23 There is a debate in literature concerning the 73 
changes in CO during the third trimester: some studies found a decline,7, 24-26 whereas others observed 74 
no change2, 5, 6, 27 or an increase towards term.28, 29 These differences have been attributed to variations 75 
in methodology and/or population characteristics.24, 30  76 
HR and SV and thus CO are very sensitive to changes in position and are highly variable among 77 
women.6 Doppler studies in the third trimester in normal pregnant subjects comparing 78 
measurements in lateral and supine positions, have shown no differences in cardiac output near 79 
term.31, 32 However, cardiovascular magnetic resonance (CMR) in pregnancy showed significant 80 
increment of left ventricle ejection fraction, SV and CO in left lateral position in third trimester pregnant 81 
subjects.33, 34 Therefore, it is highly recommended that CO-related assessments are performed in a left 82 
lateral position as early as from 20 weeks gestation. Multiple studies investigating CO during delivery 83 
using a modified pulse pressure method after arterial and central venous catheterization and CW 84 
ultrasound  suggested that SV and CO increase during labor and immediately postpartum due to pain, 85 
maternal bearing-down efforts and the increase in venous return by autotransfusion from the contracted 86 
uterus and the sudden release of inferior vena cava obstruction, which was readily accepted as common 87 
knowledge for several decades.35-41 Recent prospective studies using continuous measurement methods 88 
suggest a different perspective with similar baseline hemodynamic parameters during the course of 89 
labor (stage 1, 2 and postpartum) and substantial hemodynamic stress during contractions, without an 90 
increase in CO directly postpartum.42, 43 91 
 92 
Blood Pressure 93 
Mean arterial pressure (MAP) reduces by approximately 10% by the end of the second trimester. After 94 
this period, MAP starts to increase towards term.1 BP detection during pregnancy should be 95 
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standardized to be taken in a seated or semi-recumbent position with the arm at the level of the heart 96 
and the feet supported or on the ground.44-46 When BP measurement is performed in association with 97 
the evaluation of CO for the calculation of PVR, BP should be taken as closely as possible to the CO 98 
assessment and in the same position as during CO assessment, to provide a reliable calculation of PVR 99 
from highly variable parameters in time. 100 
BP can be obtained invasively from appropriately levelled arterial catheters or non-invasively using 101 
either a sphygmomanometer or automated oscillometric devices which are validated for use in 102 
pregnancy, all with an appropriate sized arm cuff.44, 45, 47, 48 Recent developments in technologies have 103 
provided new insight into the role of peripheral (typically brachial) and central (= aortic) BP, and the 104 
associated aortic stiffness.49 The role of aortic stiffness and central aortic BP in pregnancy remains to 105 
be fully determined.50-54  106 
 107 
Peripheral Vascular Resistance 108 
The afterload represents the mechanical opposition to the movement of blood out of the left ventricle 109 
and can be divided into: a steady component (PVR) and a pulsatile component.55 PVR is primarily due 110 
to the cross-sectional diameter of the resistance vasculature. During pregnancy the increased CO 111 
associated to the decline in MAP results in a decline in calculated PVR. The steady component of the 112 
afterload (i.e. PVR) decreases with pregnancy.1, 5, 56-58 The pulsatile component represents the load 113 
faced by the heart due to the response of the arterial tree to oscillations in pressure and flow.55 114 
The global arterial compliance increases with pregnancy, with most of the increase occurring early 115 
during gestation and remaining elevated thereafter. Reduced smooth muscle tone appears to be the 116 
likely mechanism responsible for increased vascular distensibility. The increase in the global arterial 117 
compliance appears to be one of the body’s adaptive mechanisms to accommodate greater 118 
intravascular volume without increasing mean arterial pressure. Moreover, the increased arterial 119 
compliance counterbalances the effects of reduced PVR and helps maintain the efficiency of left 120 
ventricle-to-arterial system mechanical energy transfer. Another aspect to underline is that increased 121 
compliance also balances the effect of reduced PVR on aortic diastolic pressure decay, thus preserving 122 
perfusion pressure to the coronary arteries and other vital organs.55 123 
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The reduced PVR (steady component) allows to maintain MAP within the normal range at the time of 124 
greatly increased CO.26 Therefore, concomitant changes in arterial pulsatile load during normal 125 
pregnancy, especially arterial compliance, are such that the potentially deleterious effects of PVR 126 
reduction are mitigated.55 127 
 128 
Methods of Cardiac Output measurements 129 
Invasive methods 130 
Pulmonary artery catheterization. 131 
A pulmonary artery catheter (PAC) is advanced via a brachial, subclavian or jugular vein, through the right 132 
atrium and ventricle into the pulmonary artery. The catheter has several lumens, injection and sampling 133 
ports and a thermistor and balloon at the tip, permitting various pressure (central venous pressure, 134 
pulmonary artery pressure and pulmonary capillary wedged pressure) and output measurements (illustrative 135 
video available via Kelly et al.).59 136 
The direct Fick method calculates CO by dividing the oxygen consumption (measured with a spirometer) 137 
by the difference in arterial and mixed venous oxygen content (sampled from the PAC). This method is 138 
rarely used in clinical practice. 139 
CO can also be measured by thermodilution based the law of conservation of energy. A bolus solution of 140 
known volume (5-10mL) and temperature (either ice-cooled or at room temperature) is injected as an 141 
indicator through a proximal port of the PAC and mixes with blood thereby cooling it. CO is deducted from 142 
curves of temperature difference over time between the injection site and the tip of the PAC using the 143 
modified Stewart-Hamilton equation. Intermittent CO values are obtained by averaging 3 to 5 144 
thermodilution curves.  145 
Some manufacturers (Table 1.) incorporated an electric heating filament into the PAC permitting 146 
continuous CO trend measurements of every 30-60 seconds after initial and regular subsequent calibration 147 
with the intermittent bolus technique. The obtained values do not reflect the instantaneous CO but an 148 
average over the last 5 to 15 minutes. 149 
The technique is highly invasive with substantial procedure related risks and limited to ICU settings. 150 
Catheter insertion, performing measurements and interpreting the thermodilution curves can be technically 151 
challenging and requires specific expertise and training. Despite being considered the reference method for 152 
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CO measurements, it is good to realize that even in optimal conditions the accuracy and precision of the 153 
method reflecting the “true actual CO” remains around 10-20% due to inherent technical limitations. It 154 
means that PAC, even as a reference technique, can only reliably demonstrate changes in CO of at least 15-155 
30%, being on average 0.75-1,5 L/min for a mean CO of 5 L/min in adults.60, 61 156 
While popular in intensive care settings and obstetric critical care for hemodynamic monitoring and 157 
treatment guidance until the beginning of the 21st century, controversy about its risk/benefits ratio and the 158 
development of less invasive techniques make that PAC nowadays, especially in obstetrics, has mostly been 159 
abandoned, thereby depriving us of a generally accepted reference method to compare alternatives. 160 
Recommendation: PAC should only be used on strict clinical indication in critically ill pregnant women in 161 
either an intensive care setting of obstetrical critical care unit.   162 
 163 
Less or minimally invasive methods 164 
Pulse contour and pulse power analysis and pressure recording analytical method (PRAM) 165 
Pulse contour and pulse power analysis are less invasive methods to measure CO, both in essence based on 166 
the relation between arterial pressure and SV. By analyzing the peripheral arterial pressure waveform, 167 
taking several assumptions on aortic compliance, impedance and wave reflection into account, CO can be 168 
estimated in a continuous, real time and operator independent manner. The arterial waveform is obtained 169 
by an intra-arterial line. The methods require initial calibration to account for the assumptions on aortic 170 
compliance, impedance and peripheral resistance and regular subsequent recalibration, especially after 171 
major hemodynamic changes.  172 
The PiCCO® system (Figure 1) and Volume View/EV1000® systems (pulse contour; Table 1) use 173 
transpulmonary thermodilution similar to thermodilution with PAC. They require a central venous line and 174 
femoral or axillary arterial line with thermistor tip, and are only slightly less invasive as compared to PAC, 175 
limiting their use to ICU settings. In addition to CO and central venous and intra-arterial pressure, global 176 
end diastolic volume (as a measure of preload) and extravascular lung water (as a measure of pulmonary 177 
edema) can be obtained.   178 
 179 
LiDCOplus® system (pulse power; Table 1) dilutes small boluses of lithium chloride as indicator for 180 
calibration. Lithium can be administrated via a peripheral intravenous access and measured by a disposable 181 
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sensor coupled to a peripheral arterial line. Being far less invasive, it can therefore be considered in obstetric 182 
high care settings. Lithium is contraindicated in the first trimester of pregnancy, being associated with an 183 
increased risk of Ebstein anomaly.62 However, a recent European registry-based study suggests the 184 
prevalence of Ebstein anomaly to be associated with maternal mental health problems generally rather than 185 
lithium specifically.63 The amounts of lithium used to calibrate LiDCOplus® are very low, certainly as 186 
compared to standard therapeutic doses in pregnant women with bipolar disorders, however, lithium freely 187 
crosses the placenta.64 Two recent meta-analyses addressed the long term neurodevelopment outcomes in 188 
offspring with in utero exposure to lithium.65, 66 While preclinical data in animals suggested a potential 189 
adverse effect, clinical data in humans, although limited to 97 children, seem reassuring.67 The 190 
manufacturer does not advice against the use of LiDCOplus® in pregnant woman or during breast feeding, 191 
except in the first trimester.  192 
 193 
The same three manufacturers also developed systems requiring only a peripheral arterial line without prior 194 
calibration (Table 1). The assumptions for the algorithms are based on patient characteristics and experience 195 
obtained with their calibrated alternatives. Some of them permit calibration by an external source such as 196 
ultrasound. The pressure recording analytical method (PRAM) also derives CO continuously from a 197 
peripheral arterial waveform without need for prior calibration using a different algorithm (Table 1). 198 
LiDCOplus® has been validated in 18 postpartum severe preeclamptic women against PAC and showed 199 
good agreement with a low bias and percentage error within 30%.68 It has also been used in the second and 200 
third trimester of pregnancy.69, 70 It can serve as an alternative minimally invasive reference method in 201 
pregnant (after the first trimester of pregnancy) and postpartum women. It is mostly suited for short term 202 
real time continuous CO trend monitoring. 203 
Most other systems (LidCOrapid®, FloTrac®, PiCCO®, ProAQT®, MostCareup®) have been used, but 204 
not been validated in pregnant women.71-76 Given the unique effects of pregnancy on arterial wall 205 
composition and function, it is questionable whether these techniques can be reliably used without prior 206 
calibration or validation, especially in rapidly changing hemodynamic conditions.  207 
Although substantially less invasive compared to PAC, the abovementioned techniques require insertion of 208 
arterial lines and performing dilution procedures to calibrate the devices, which in turn requires specific 209 
medical skill, training and learning curves. 210 
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Recommendation: We recommend prior validation of these techniques in pregnancy before further use in 211 
clinical or research setting. LiDCOplus® can be used for short term real time continuous CO trend 212 
monitoring after the first trimester of pregnancy, taking the concerns on peripheral arterial cannulation and 213 
lithium use into account.  214 
 215 
Transesophageal Doppler monitor (TDM) 216 
With Transesophageal Doppler monitoring a 6mm Doppler probe is inserted either nasally or orally into 217 
the lower esophagus. It is then oriented and aligned to optimally measure blood flow using either continuous 218 
or pulsed wave Doppler in the thoracic aorta (Table 1). Continuous real-time CO can be calculated by an 219 
algorithm assuming a correctly estimated fixed aortic cross sectional area, fixed blood flow distribution in 220 
the aorta and provided good probe alignment and limited probe movements. While most commonly used 221 
with sedation, the device is also tolerated in awake individuals as the procedure and discomfort is similar 222 
to the insertion of a nasogastric tube, notwithstanding the increased risk of aspiration in pregnant women. 223 
To obtain the necessary waveforms, experience with an intra-esophageal probe is required.  224 
TDM has been validated against PAC in 17 women with severe preeclampsia. While absolute values of 225 
cardiac output were consistently underestimated by 36%, in women above 40 years of age the accuracy 226 
increased.77, 78 227 
Recommendation: TDM could potentially be of value for trend monitoring but needs further validation in 228 
pregnant women, especially in younger women. 229 
 230 
Non-invasive methods 231 
Cardiovascular magnetic resonance imaging  232 
CO can be calculated with CMR using either cine-CMR or phase contrast imaging technique without need 233 
for ionizing radiation or contrast agents. Cine-CMR produces high resolution images discerning the 234 
myocardium from the blood pool allowing detailed 3D measurements of cardiac dimensions during systole 235 
and diastole. It permits accurate and reproducible calculation of the SV without the necessity to rely on 236 
geometric assumptions. The phase contrast imaging permits flow analysis in a similar way as Doppler 237 
ultrasound, by relating measured phase shifts produced by moving blood in a vessel to velocity. When 238 
measured at the aortic root along with its diameter, LV output can be calculated. CMR data are usually 239 
 10 
acquired over multiple cardiac cycles with the subject holding its breath. CMR provides highly accurate 240 
information on cardiac functioning but only during the examination and cannot be used for continuous 241 
monitoring. In non-pregnant individuals, CMR is considered the reference method for non-invasive 242 
assessment of CO.79, 80 It is often the method of choice in complex structural heart disease. Operator 243 
dependency is less than for echocardiography, but CMR still requires specific expertise in obtaining high 244 
quality images and interpretation of the images. Thereby, a specific MRI device and set-up is needed. 245 
Subjects must lie still in a narrow tunnel during the image acquisition, which can be experienced as 246 
claustrophobic, especially in late pregnancy. The subject must be free of devices that might affect or react 247 
with the magnetic field, limiting the possibilities of simultaneous comparison of CO with other techniques. 248 
The availability and also costs make that it is not suitable for routine or bedside use. 249 
CMR is considered safe in the second and third trimester of pregnancy. While caution is advised in the first 250 
trimester, clinical data of occasional use seem to indicate that it is equally safe.81 CMR has been evaluated 251 
next to TTE in 34 pregnant women in which CMR was proven to have a higher reproducibility and smaller 252 
intra- and inter-observer variability.82 As with other methods it is essential not to forget to position pregnant 253 
women in a left lateral position as early as from 20 weeks gestation as CMR studies have clearly showed 254 
the effect of caval compression by the pregnant uterus on the CO.33, 34 A retrospective study by Romagano 255 
et al. showed CMR findings can alter the clinical management in pregnant women with complex cardiac 256 
disease or suspected aortic pathology in addition to the findings by TTE.83 CMR seems to be an accurate 257 
and precise method to assess maternal hemodynamics and is especially helpful in women with complex 258 
cardiac anatomy of suspected cardiac pathology. 259 
Recommendation: CMR could be considered as a reference method for CO assessment in pregnancy. 260 
However costs, availability and specific set-up limit its use for CO measurements in clinical and research 261 
settings.  262 
 263 
Transthoracic echocardiography 264 
Echocardiography and Doppler ultrasound have been widely used for the detection of CO during 265 
pregnancy,3-8, 11-15, 24-30, 32, 56, 84-86 demonstrating to be reliable against the invasive techniques.3, 87, 266 
88 The general availability of the technique, low cost, portability and true noninvasiveness, make 267 
TTE an ideal method for rapid hemodynamic assessment in pregnancy. 268 
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M-mode echocardiography 269 
Measurement of CO with this method is based on the calculation of left ventricular diastolic and 270 
systolic volumes from M-mode measurements. Left ventricular end-diastolic and end-systolic 271 
diameters (D) are detected in the parasternal long axis view during M-mode tracing (Figure 2).89 Left 272 
ventricular volumes (V) are calculated according to the Teichholz formula from end-diastolic and 273 
end-systolic diameters V = 7D3 /(2,4 + D).90 SV is calculated as the difference between end-diastolic 274 
and end-systolic volumes. CO is calculated as the product of SV and HR derived from 275 
electrocardiographic monitoring. Ejection fraction (EF) also can be calculated as the fractional 276 
reduction of the volumes (Supplementary video available on request). 277 
The Teichholz formula may potentially underestimate left ventricular volumes, particularly in 278 
patients with an extremely elliptic shaped left ventricle, with minor to major hemiaxis ratio < 0,33.91, 279 
92 Because of the assumptions of the shape of the LV, which may change differentially across pregnancy 280 
in different mothers, this method has several limitations in the correct estimation of SV and CO.93  281 
Doppler studies 282 
The Doppler method estimates the area under the curve of the aortic flow velocity waveform while two 283 
dimensional echocardiography determines the area of the aortic valve. The diameter of the left ventricular 284 
outflow tract (LVOT) during systole is measured in the 2D parasternal long axis view; the aortic cross 285 
sectional area (CSA) is calculated from this diameter and is multiplied by the time-velocity integral of aortic 286 
flow (Figure 3). The SV is therefore obtained and CO can be calculated. This method has been validated 287 
against thermodilution in 3 studies including altogether 34 severally ill pregnant women.3, 87, 88  288 
LVOT CSA is determined from the maximum systolic diameter measured at the level of the valve annulus 289 
and averaged over three to five cardiac cycles.94 This can be done using M-mode or 2-D echocardiography 290 
although CO calculated by the latter method correlates most closely with invasive measurements.4 291 
The time-velocity integral of aortic flow can be measured with continuous wave Doppler (CW) or pulsed 292 
wave Doppler (PW). CW method is not incorrect, but in this case the velocity profile reflects the highest 293 
velocity of the moving blood cells; the measurement with CW is related to the cross sectional area (CSA) 294 
of the aorta more than to the annulus of the aortic valve. This will influence the calculation of SV and CO, 295 
which will result in higher values than those detected with PW.94 This is a general problem and a limitation 296 
when comparing SV, CO, and PVR from different studies performed with different methods (CW or PW). 297 
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Most studies in pregnancy have measured flow across the aortic valve either recording velocities from the 298 
suprasternal notch using CW Doppler5, 8, 25, 95 or from the apical five-chamber view using PW Doppler,3, 21, 299 
87, 88 one study reports on both methods.28 Also the coefficient of variation (6,7%) is lower as compared to 300 
Teichholz or Simpson method.96  301 
An advantage of the Doppler method is clearly its assessment of ‘hemodynamics’, as it captures the blood 302 
velocity profile quite accurately. However, it is important to note that this method will not provide any 303 
information on the volumes of the heart in the filling state, nor following contraction. 304 
2D and 3D echocardiography 305 
LV volumes can be measured using 2D or 3D echocardiography. The detection of LV end-diastolic and 306 
end-systolic volumes allows for the calculation of SV and, therefore CO. Volume calculations derived from 307 
linear measurements for the calculation of SV, in fact, may be inaccurate, since they rely on the assumption 308 
of a fixed geometric LV shape. Therefore, the Teichholz and Quinones methods are no longer recommended 309 
for clinical use, as outlined in a previous paragraph.95, 97 310 
The most commonly used method for 2D echocardiographic volume calculations is the biplane method of 311 
disks summation (modified Simpson’s rule), which is the recommended 2D echocardiographic method in 312 
any patient population (Figure 4).97 This method requires experienced echocardiographers in order to obtain 313 
reliable volume measurements and is much more operator-dependent than the Doppler technique. Besides, 314 
in pregnancy it can be more difficult to obtain an acceptable acoustic window due to body 315 
composition changes. Several studies have used 3D echocardiographic for the detection of left ventricular 316 
volumes in healthy subjects with a wide variability from study to study probably due to differences in 317 
populations, echocardiographic equipment, and analysis software, as well as variability in measurement 318 
techniques.97 319 
Despite ultrasound experience in most obstetric and fetal maternal medicine specialists, TTE requires 320 
specific echocardiographic expertise which can be obtained by training from cardiologists or certified 321 
echocardiographers.  322 
Recommendation: TTE has been mentioned as the new reference standard for measuring CO in 323 
pregnancy. However, it remains a specialized technique in which obstetricians and/or obstetric 324 
anesthesiologists are only rarely trained. We therefore recommend more obstetricians with 325 
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interest in maternal critical care should be trained in the technique to enhance the availability of 326 
TTE for hemodynamic monitoring in clinical care. 327 
 328 
Alternative Doppler technique  329 
Lately a new method has been introduced in pregnancy for the detection of SV and CO, the UltraSonic 330 
Cardiac Output Monitor (USCOM 1A®).9, 10, 98-108 This is a non-invasive Doppler method to determine 331 
hemodynamic values by placing a non-imaging continuous-wave Doppler transducer on the suprasternal 332 
notch to determine ascending transaortic blood flow (Figure 5). After manually adding a woman’s BP, body 333 
mass and height into the system, USCOM 1A® is able to calculate the following cardiovascular parameters: 334 
CO, HR, PVR, inotropy index (INO) and time flow correct (TFC). This method is based on an algorithm, 335 
which takes into account the patient's height, to provide the outflow tract diameter. A limitation of this 336 
assumption is that it does not take into consideration a possible modification of aortic diameter and 337 
compliance during pregnancy. On the other hand it is easy to use and much less operator-dependent 338 
compared to echocardiography. A individual training session before using USCOM 1A® is advised, 339 
including up to 50 test cases prior to the use for research of clinical purposes.106  340 
To date, the validation of this method during pregnancy was performed against 2-D and 3-D TTE in 341 
respectively 98 and 92 women and showed good reproducibility, but variable accuracy and precision 342 
depending on which trimester and which USCOM waveform tracing technique was used.102, 106  343 
Recommendation: Despite the necessity for further validation, USCOM 1A® with its user friendly profile 344 
is promising and can provide important information about the maternal hemodynamic condition in clinical 345 
settings and at the outpatient clinic. 346 
 347 
Inert gas rebreathing technique 348 
Using the technique, an O2 enriched mixture containing of two inert gases, one blood soluble (N2O) and 349 
one insoluble (SF6), are administered through a closed breathing assembly. Relative levels over a few 350 
respirations are measured by a gas analyzer in the mouthpiece, from which the Innocor® monitor calculates 351 
CO relying on Fick’s principle (Figure 6). The method is based on the assumption that the rate of 352 
disappearance of the blood soluble gas from the alveolar space is proportional to the pulmonary blood flow 353 
being CO. The insoluble gas helps to ascertain the long volume from which the soluble gas disappears. The 354 
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technique can be used in rest and during exercise and is operator independent.109, 110
 
It is good to mention 355 
the inert gas rebreathing technique only represents the ventilated part of the lungs, so in subjects with 356 
increased alveolar dead space assumptions on CO may not hold. Also, in subjects with pulmonary edema 357 
such as in severe preeclampsia, there is no steady respiratory state and the assumptions may not apply. The 358 
technique has been validated in adults with heart failure against PAC using thermodilution and direct Fick 359 
method.109 While used in several studies in pregnant women, the method has not been validated in 360 
pregnancy.17, 110-112  361 
Recommendation: Further evaluation of the inert gas rebreathing technique during pregnancy, including 362 
the feasibility of the method for instance during labor, is needed prior to implementation in clinical care.  363 
 364 
Impedance cardiography and bioreactance 365 
The technique uses electrodes to transmit a very low amplitude high frequency current through the thorax 366 
and detect impedance changes (bioimpedance) or phase shifts (bioreactance) induced by changes in blood 367 
flow throughout the cardiac cycle. Interferences from other sources (e.g. respiration, movement, other 368 
devices) are filtered out. From these changes SV and CO can be derived. Some techniques also rely on 369 
impedance changes measured more peripherally. Several devices exist, each relying on specific algorithms 370 
with distinctive features and filters to remove distortions intended at improving accuracy and signal 371 
stability. As such, by using 4-6 cutaneous electrodes on the thorax, CO can be measured in a continuous, 372 
easy, relatively cheap and operator independent way with high repeatability (E.g. Figure 7).113 Some 373 
devices reflect the actual instantaneous CO and can be used to assess rapid changes, others reflect mean 374 
CO over the last minute. 375 
Given its accessibility and ease of use which makes it operator independent, impedance cardiography (ICG) 376 
became very attractive for CO measurements in both pregnant and non-pregnant populations.96, 114-117 377 
Nevertheless, most validation studies in both non-pregnant and pregnant women, using any of the available 378 
devices, have not been able to show sufficient accuracy and precision as compared to reference methods 379 
like PAC or TTE in reflecting absolute CO values.10, 96, 105, 106, 117-121 As such, all these devices (Table 1) are 380 
at the moment probably not suited in reflecting “true CO” values. Nevertheless these techniques might be 381 
very convenient to monitor trends and relative changes over a shorter period of time as e.g. during labor, 382 
caesarean section or for monitoring therapy in acute conditions.  383 
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Recommendation: Before further use in pregnancy for trend monitoring we would recommend validation 384 
of bioimpedance and bioreactance devices for this purpose against established reference methods, which is 385 
under way for several devices.   386 
 387 
Non-invasive pulse contour analysis 388 
Similar to the minimally invasive counterparts, these devices rely on the on the relation between arterial 389 
pressure and SV and derive CO from the peripheral arterial waveform. The arterial wave form is obtained 390 
by several sometimes innovative methods varying from oscillometric BP cuffs to high tech volume 391 
clampfinger clips at various sites (brachial artery, finger, ankle). Multiple non-invasive pulse contour 392 
analysis devices have been developed over the last years (Table 1), all easy to use and operator independent 393 
(E.g. Figure 8). Nevertheless, validation studies both outside and during pregnancy often show 394 
inappropriate accuracy for absolute measurements.  395 
Recommendation: While potentially interesting for short term trend monitoring, the same concerns and 396 
limitations apply as for their minimally invasive analogues and prior validation during pregnancy for this 397 
purpose remains essential before implementation in clinical or research setting.122, 123  398 
 399 
Comparing methods of CO measurement 400 
When comparing techniques for CO determination both accuracy (potential of the technique in reflecting 401 
the “true CO”), as well as other factors like ease of use, degree of invasiveness, costs and operator 402 
dependency are to be taken into account. Ideally, the accuracy and precision (how often the same value is 403 
obtained if measurements are repeated) of a method are compared to a reference method. Usually an 404 
investigated technique is considered appropriate if accuracy and precision are at least equivalent to the 405 
reference method. However, one could still consider the acceptance of a technique with inferior accuracy 406 
and precision if the additional benefits outweigh this inferiority for its specific intended use. 407 
It is important to realise that CO, being the product of HR and SV, is highly variable in time. Therefore 408 
comparative measurements are best performed simultaneously at the exact same time. Also, all reference 409 
methods have inherent errors which can be calculated by assessing the coefficient of variation (calculated 410 
as the standard deviation / mean). As the traditional reference method, PAC with thermodilution, is not 411 
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justifiable for comparative studies in pregnant woman anymore, LidCOplus®, CMR and TTE (using 412 
Doppler method) are probably the best alternatives, all with their inherent limitations. 413 
 414 
Several statistical approaches to validate new methods of CO measurement have been used in the past. 415 
Bland and Altman introduced a method in 1986 where bias (mean difference) and limits of agreements 416 
(1.96 * SD around the bias, wherein 95% of all points fall) are depicted in a simple plot.124  417 
For absolute CO measurements, Critchley and Critchley125 suggested that in all comparisons between 418 
techniques, mean CO, bias, limits of agreement and percentage error (limits of agreement divided/mean 419 
CO; PE) should be reported. The accuracy and precision of an investigated technique is traditionally 420 
considered sufficient if bias is low and PE is within +-30 %. However, this is based on the precision of 421 
PAC thermodilution technique and ideally the calculated precision of the used reference method in the 422 
study should be taken into account instead of the generally accepted precision of thermodilution.125  423 
 424 
To compare ability of CO monitoring devices, differences in CO are best plotted in a four quadrant or polar 425 
plot. Concordance rate, angular bias and radial limits of agreement can be calculated and added along with 426 
an exclusion zone for small differences in both graphs. The four quadrant plot is a visually more intuitive 427 
method to show trending ability, the polar plot is statistically a little more advanced but more difficult to 428 
interpret.126, 127 429 
For more in-depth information on the statistical approach of comparing methods, we recommend several 430 
recent reviews by Odor et al., Hapfelmeier et al., Cecconi et al., Saugel et al. and Critchley et al..60, 61, 126-431 
128 432 
 433 
Interpreting Cardiac Output measurements in pregnancy: when and how to index or normalize?  434 
The scientific basis and accuracy of CO measurement aside, the issue of how to interpret CO in pregnancy 435 
remains a contentious topic.  436 
Normal CO at rest ranges between 4-8 L/min in healthy non-pregnant women, but can rise up to more than 437 
15-20 L/min during exercise.129-134 It shows that CO is a highly variable parameter which can easily be 438 
raised or lowered by modifying SV and/or HR. This flexibility permits the cardiovascular system to both 439 
meet varying tissue oxygen requirements and maintain cardiovascular homeostasis in a wide range of 440 
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conditions, but requires a complex interplay with other cardiovascular parameters like vascular resistance, 441 
compliance, redistribution properties etc.. 442 
This variability is also influenced by body size, basal metabolic rate, degree of fitness, advancing age and 443 
gestational age. These factors have a significant impact on maternal tissue metabolic oxygen demands with 444 
advancing gestation in pregnancy, and by definition, impact on the interpretation of measured CO data in 445 
pregnancy. For example, a CO of 6 L/min is considered physiologically normal in a 35yr old woman 446 
weighing 60kg at 24 weeks’ gestation, but may be considered hypodynamic in a 25yr old who reaches a 447 
weight of 90kg at 41 weeks’ gestation. 448 
Determining normality within this variability can thus become challenging. Researchers and clinicians have 449 
divided approaches to overcome this issue. Some prefer to use the raw, absolute data despite its variability, 450 
considering that this actual value is the most accurate. Others opt to index the absolute values in an attempt 451 
to correct for the abovementioned factors, still acknowledging that none of the indexing tools can fully 452 
compensate for the whole complexity of the variation and the inherent limitations of the indexing tool itself 453 
which could introduce an additional error in the value. 454 
 455 
Indexing can be done for actual maternal BSA (body surface area), pre-pregnancy BSA or using pregnancy 456 
CO ranges: 457 
Indexing by maternal BSA at each visit 458 
The relationship between body mass and metabolic rate is negatively allometric, resulting in metabolic rate 459 
(and by definition oxygen demand) being more closely related to BSA than BMI.135 Neither BSA nor BMI 460 
changes accurately reflect changes in pregnancy due to the uterus, amniotic fluid and fetus and maternal 461 
body composition of fat and muscle so any use of BSA or BMI must take into account the inherent 462 
assumptions involved in this calculation. Even correction of CO for BSA has a known limitation – 463 
inaccuracy at extremes of body weight and height, where this indexing is likely to be unreliable whether 464 
pregnant or not. A limitation specific to pregnancy is the assumption that metabolic activity in pregnancy 465 
is the same as the non-pregnant state. Available data indicates that the basal metabolic rate in pregnancy is 466 
some 1.5-times higher than the non-pregnant state, suggesting that indexing for BSA is systematically 467 
under-correcting for the potential increase in pregnancy metabolic and oxygen demands.136 468 
Indexing by pre-pregnancy BSA 469 
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This allows all measurements to start from the same ‘point’ but does not take into account for change in 470 
weight and significant increase in metabolic demands with advancing pregnancy. 471 
Normalizing using pregnancy CO reference ranges 472 
Gestational age and preferable device specific reference ranges for hemodynamic parameters in normal 473 
pregnancy constructed from women of differing ages and weights would permit the interpretation of 474 
measured CO as a fraction of expected CO.137 Individual values can then be converted to gestation specific 475 
z-scores, multiples of the median (MoMs) or percentiles to allow comparison. Although this represents the 476 
most accurate way to index CO measurements in pregnancy, the availability of such constructed reference 477 
ranges is currently limited. 478 
 479 
Despite all controversy, it is probably much more important to consider when and how to index rather than 480 
whether or not to index. There are certainly situations in which indexing can offer a different perspective 481 
and, thus, be of additional value in interpreting the raw absolute data. It very much depends on the indication 482 
why cardiac output was determined. 483 
When comparing single measurements between individuals or assessing one’s cardiovascular status based 484 
on a single measurement (e.g. to predict her risk of preeclampsia or degree of shock), indexing can offer a 485 
distinctive perspective that helps interpreting the absolute data. 486 
When comparing evolution in CO over a longer (e.g. CV adaptation in the course of pregnancy) or shorter 487 
(e.g. effects of treatment, CO during course of labor or acute illnesses) period of time, the differences 488 
between trajectories or absolute values are of importance and the individual becomes their own control. 489 
The additional value for indexing is then far less prominent. 490 
 491 
Overall recommendations for clinical use 492 
 At present, there is no ideal method for CO measurement in pregnancy. All methods have 493 
particular strengths and limitations. Which method is best selected, strongly depends on the 494 
indication why CO needs to be assessed.  495 
 PAC should only be used on strict clinical indication in critically ill pregnant women, which is 496 
extremely rare. 497 
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 CMR provides accurate CO values in pregnancy and could be considered as a reference technique 498 
for comparison, if available and simultaneous measurements are possible.  499 
 TTE using Doppler technique is more readily available and can be considered as an alternative 500 
reference technique for CO determination in pregnancy. 501 
 Taking the necessity for an arterial line and concerns of lithium use in pregnancy into account, 502 
pulse pressure analysis using lithium calibration with the LiDCOplus® system can be used for 503 
accurate CO determination and trend analysis. 504 
 Other techniques like non-imaging continuous-wave Doppler, impedance cardiography, inert gas 505 
rebreathing techniques and non-calibrated pulse contour analysis can be promising, but need prior 506 
validation in pregnancy for absolute values and/or trend monitoring.  507 
 Different techniques measure in different ways relying on different assumptions and should not 508 
be used interchangeably. 509 
 When individual measurements of CO over longer periods in time (e.g. each trimester) are 510 
indicated, CMR, TTE (Doppler) or inert gas rebreathing technique is the preferred method. 511 
 When continuous monitoring of CO over a shorter period of time is indicated (e.g. during labor, 512 
or to monitor short-term treatment), pulse pressure/contour analysis or impedance cardiography is 513 
most applicable. 514 
 When rapid and instantaneous evaluation of CO is indicated, TTE or USCOM 1A® could be the 515 
method of first choice. 516 
 When CO is assessed in a supine pregnant woman, she should be turned to a left lateral position 517 
of at least 15 ° as from 20 weeks of gestation. 518 
 Inherent limitations in the precision of most reference techniques mean that only changes of at 519 
least 20% can be reliably be considered as valid.  520 
 BP should be taken in the seated or semi-recumbent position with the arm at the level of the heart 521 
and the feet supported or on the ground.  522 
 When BP is taken for the calculation of PVR, it should be taken at the end of the examination in 523 
the same position as during the method used to determine CO. 524 
 Depending on the indication for CO determination, indexing can be of additional value in 525 
interpreting absolute CO values. 526 
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 In case of indexing of the hemodynamic parameters, this is ideally performed from - where 527 
available - device specific, established reference ranges from normal pregnancies that take into 528 
account maternal age, height, weight and gestational age.  529 
 Comparison of techniques should be performed using mean values bias, limits of agreement and 530 
percentage error for absolute values and four quadrant plot or polar plot for trend monitoring. 531 
 532 
Recommendations for future research 533 
 Non-invasive methods for measurement of CO should be validated in both healthy and 534 
complicated pregnancies.  535 
 Hemodynamic adaptations should be studied in pregnancy complications such as preeclampsia. 536 
 The effects of therapies on hemodynamic values in hypertensive and critically ill pregnant women  537 
should be investigated. 538 
 The hemodynamic responses to and the value of functional hemodynamic testing during 539 
pregnancy should be studied.  540 
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Table 1: Overview on methods for cardiac output monitoring. 935 
 936 
Invasiveness Technique Device (Manufacturer) if applicable 
Invasive 
 Pulmonary artery catheterization with 
intermittent thermodilution 
 
Pulmonary artery catheterization with 
thermodilution and continuous CO 
measurements 
Swan Ganz continuous cardiac output catheters (Edwards Lifesciences Corporation) 
TDQTM and OptiQ® continuous cardiac output catheter (ICU Medical Inc.) 
Less or minimally invasive 
 Peripheral pulse contour analysis with 
transpulmonary thermodilution calibration 
Volume View/EV1000® (Edwards Lifesciences Corporation) 
PiCCO® (PULSION medical systems SE) 
Peripheral  pulse power analysis with lithium 
calibration 
LiDCOplus® (LiDCO) 
Peripheral pulse contour analysis without 
calibration 
ProAQT® (PULSION medical systems SE) 
FloTrac/Vigileo® (Edwards Lifesciences Corporation) 
CardioFloTM (ICU Medical Inc.) 
Peripheral pulse power analysis without 
calibration 
LiDCOrapid® (LiDCO) 
Peripheral pressure recording analytical 
method without calibration 
MostCareup® (Vytech) 
Transesophageal continuous-wave Doppler 
monitor 
CardioQ-ODM® (Deltex Medical Ltd.) 
Transesophageal M-mode and pulsed-wave 
Doppler monitor 
HemoSonic 100® (Arrow International) 
Non-invasive 
 Cardiovascular magnetic resonance imaging  
Transthoracic echocardiography  
Non-imaging continuous-wave Doppler  USCOM 1A® (Uscom Limited) 




PhysioFlow® (Manatec Biomedical) 
BioZ® (CardioDynamics) 
Niccomo/Cardioscreen 2000/Cardioscreen 1000 (Medis) 
AcqKnowledge® (BIOPAC systems Inc.) 
NCCOM® (Bomed Medical) 
ICG (Philips Medical Systems) 
NICOMON (Laresen and Toubro Ltd.) 
CSM3000 (Cheers Sails Medical) 
Whole body bioimpedance NICaS® (NImedical) 
Bioreactance 
 
Cheetah NICOM® (Cheetah Medical Inc.) 
AESCULONTM (Osypka Cardiotronic) 
Non-invasive pulse contour analysis 
 
Vicorder® (SMT medical GmbH&Co. KG) 
Mobil-O-Graph® (I.E.M. GmbH) 
SphygmoCor® (AtCor Medical Holdings Limited) 
ClearSight® (Edwards Lifesciences Corporation) 
CNAP® (CNSystems Medizintechnik GmbH) 
Finometer PRO® (Finapres Medical Systems B.V.) 
Portapres® (Finapres Medical Systems B.V.) 
Non-invasive pulse power analysis with 
continuous non-invasive blood pressure  
LiDCOrapid® with CNAPTM (LiDCO) 
 937 
